%0 Journal Article
%T Prognostic Biomarkers and EBV Infection Research in Diffuse Large B-Cell Lymphoma of the Palatine Tonsils
%A Marinho Marques
%A Estela Luz
%A Michael Hummel
%A Maria das Gra£¿as Vieira
%A Regina C¨¦lia Bahia
%A Maria Cristina Oliveira
%A Eduardo Martins Netto
%A Ivana Luz
%A Iguaracyra Ara¨²jo
%J ISRN Oncology
%D 2012
%R 10.5402/2012/652682
%X Diffuse large B-cell lymphoma represents approximately 30%¨C40% of all diagnoses of non-Hodgkin¡¯s Lymphoma and may represent up to 80% of all lymphomas that arise in the palatine tonsils. Several studies have attempted to correlate clinical, laboratorial, and tissue factors with the prognosis of the lymphomas, such as the International Prognostic Index, the tissue expression of some proteins, and the lymphocyte count at the time of diagnosis, as well as to correlate Epstein-Barr virus (EBV) infection with worse prognoses. Patients with palatine tonsil DLBCL, from Salvador, Bahia, Brazil, were studied in order to identify prognostic factors. Twenty-four patients with DLBCL were studied. The factors that negatively influenced the patients¡¯ survival rates were the lymphocyte count at the time of diagnosis <1.000/mm3 and the Bcl-2 protein expression. There was no CD5 expression in these lymphomas, and neither was there an association with EBV infection. 1. Introduction The palatine tonsils, along with the nasopharyngeal lymphoid tissue, the base of the tongue, and the oropharyngeal wall make up Waldeyer¡¯s ring. This ring is located at the entrance of the respiratory and digestive tract, being the second most common site of extranodal lymphomas, after the gastrointestinal tract [1, 2]. These tumors represent 15 to 20% of all lymphomas and half of the head and neck lymphomas. Approximately 50% of Waldeyer¡¯s ring lymphomas arise in the palatine tonsils in presentation, and in approximately 20% of the cases they are bilateral [3]. Most lymphomas found in the palatine tonsils are the B-cell type, and, of these, diffuse large B-cell lymphoma (DLBCL) represents most of the cases, reaching as much as 80% in some of the groups studied [3, 4]. Although morphologically indistinct, some molecular studies support the hypothesis that DLBCL makes up a heterogeneous group of lymphomas that has different prognostic implications [5]. Classically, the International Prognostic Index (IPI) has been used to predict the survival of patients with DLBCL [6]; however, it is not useful in all cases. Studies using DNA microarray analysis show that the DLBCL gene expression profile similar to B cells germinal center would have a better clinical prognosis than the profile similar to activated B cells [5, 7]. Transposing this gene profile to a protein expression, Hans et al. [8] proposed an algorithm to classify DLBCL patients, using three immunohistochemical markers (CD10, Bcl-6, and MUM1). The profile that was similar to the germinal center (GC) presented a better survival rate than the
%U http://www.hindawi.com/journals/isrn.oncology/2012/652682/